

ab
C1
B2
B1

specifically binds a PHELIX protein having the amino acid sequence of SEQ ID NO: 2, and which comprises amino acid residues 140-154 of SEQ ID NO: 2.

61. (Unchanged) The PHELIX polypeptide of claim 60, further comprising a heterologous polypeptide.

ab
C2
B3
B1

68. (Amended) An isolated polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO: 2 over the entire length of SEQ ID NO: 2, wherein the polypeptide is recognized by an antibody that specifically binds a PHELIX protein having the amino acid sequence of SEQ ID NO: 2 that is a conservative substitution mutant of a protein having the amino acid sequence of SEQ ID NO: 2.

69. (Unchanged) The PHELIX polypeptide of claim 68, further comprising a heterologous polypeptide.

74. (Unchanged) A PHELIX polypeptide produced by culturing a host cell that contains an expression vector that comprises an isolated polynucleotide selected from the group consisting of:

- (a) a polynucleotide having the sequence as shown in FIG. 2 (SEQ ID NO: 1), wherein T can also be U;
- (b) a polynucleotide having the sequence as shown in FIG. 2 (SEQ ID NO: 1), from nucleotide residue number 735 through nucleotide residue number 1949, wherein T can also be U;
- (c) a polynucleotide encoding a PHELIX polypeptide whose sequence is encoded by the cDNA contained in the plasmid as deposited with American Type Culture Collection as Accession No. 98956; and
- (d) a polynucleotide encoding a PHELIX protein having the amino acid sequence shown in FIG. 2 (SEQ ID NO: 2).

75. (Unchanged) The PHELIX polypeptide of claim 74, further comprising a heterologous polypeptide.

76. (Unchanged) A composition for eliciting formation of antibodies directed to a cell that expresses a PHELIX protein, the composition comprising:

- (a) a PHELIX protein according to claim 54; and
- (b) a pharmaceutically acceptable carrier.

B4 1077. (Amended) A composition for eliciting formation of antibodies directed to a cell that expresses a PHELIX protein, the composition comprising:

- (a) an immunogenic portion of a PHELIX protein according to claim ³60; and
 - (b) a pharmaceutically acceptable carrier.
-